Cargando…

P1190: OUTCOMES BY BCL2 AND MYC EXPRESSION AND REARRANGEMENTS IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA FROM THE POLARIX TRIAL

Detalles Bibliográficos
Autores principales:	Morschhauser, F., Jiang, Y., Jardin, F., Herrera, A. F., Sehn, L. H., Herbaux, C., Flowers, C., Phillips, T., López Guillermo, A., Diefenbach, C., Gregory, G. P., Kim, A., Barbui, A. M., Balasubramanian, S., Harris, W., Hirata, J., Paulson, J. N., Lee, C., Lenz, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430026/ http://dx.doi.org/10.1097/01.HS9.0000847624.27308.c9

Ejemplares similares

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial
por: Song, Yuqin, et al.
Publicado: (2023)

P1191: ANALYSIS OF PERIPHERAL NEUROPATHY USING CLINICIAN- AND PATIENT-REPORTED OUTCOMES IN THE POLARIX STUDY
por: Trněný, M., et al.
Publicado: (2022)

Status of the Polarix-TDS Project
por: Craievich, Paolo, et al.
Publicado: (2018)

Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial
por: Johnson, Peter W. M., et al.
Publicado: (2023)

Pion polarizabilities and H(1190)-meson
por: Lvov, A I, et al.
Publicado: (1985)

P1192: ASIA SUBPOPULATION ANALYSIS FROM THE PHASE III POLARIX TRIAL
por: Song, Y., et al.
Publicado: (2022)

Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
por: Li, Weiping, et al.
Publicado: (2019)

Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements
por: McPhail, Ellen D., et al.
Publicado: (2018)

R-split-EPOCH plus high dose methotrexate in untreated diffuse large B cell lymphoma with MYC rearrangement or double expression of MYC and BCL-2
por: Sun, Peng, et al.
Publicado: (2021)

Plasmablastic lymphoma with MYC::IGH fusion and BCL2 rearrangement
por: Barouqa, Mohammad, et al.
Publicado: (2022)

High-Grade B-Cell Lymphoma (HGBL) with MYC and BCL2 and/or BCL6 Rearrangements Is Predominantly BCL6-Rearranged and BCL6-Expressing in Taiwan
por: Tsai, Cheng-Chih, et al.
Publicado: (2021)

Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6)
por: Witte, Hanno M., et al.
Publicado: (2023)

TdT Positive Lymphoma with MYC, BCL2 and BCL6 Rearrangements: A Review of Diagnosis and Treatment
por: Singh, Aditi, et al.
Publicado: (2022)

The PolariX-TDS Project: Bead-Pull Measurements and High-Power Test on the Prototype
por: Craievich, Paolo, et al.
Publicado: (2019)

Mutational landscape of high-grade B-cell lymphoma with MYC-, BCL2 and/or BCL6 rearrangements characterized by whole-exome sequencing
por: Künstner, Axel, et al.
Publicado: (2021)

1190. Dual-Plasmid Technology for Precision Genome Editing in Staphylococcus aureus
por: Reish, Jennifer, et al.
Publicado: (2020)

MYC Immunohistochemistry Predicts MYC Rearrangements by FISH
por: Nwanze, Julum, et al.
Publicado: (2017)

Targeting BCL2 with venetoclax is a promising therapeutic strategy for “double-proteinexpression” lymphoma with MYC and BCL2 rearrangements
por: Uchida, Akiko, et al.
Publicado: (2019)

P1280: TARGETED INHIBITION OF DHODH IS SYNERGISTIC WITH BCL2 BLOCKADE IN LYMPHOMA WITH CONCURRENT MYC AND BCL2 REARRANGEMENT
por: Mo, W., et al.
Publicado: (2022)

Copy Number Alteration and Mutational Profile of High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements, Diffuse Large B-Cell Lymphoma with MYC-Rearrangement, and Diffuse Large B-Cell Lymphoma with MYC-Cluster Amplification
por: Miyaoka, Masashi, et al.
Publicado: (2022)

Double-hit lymphoma (rearrangements of MYC, BCL-2) during pregnancy: A case report
por: Xie, Fan, et al.
Publicado: (2021)

Su1190 IS THERE AN ASSOCIATION BETWEEN SUBSTANCE DEPENDENCE AND MICROSCOPIC COLITIS OR EOSINOPHILIC COLITIS?
por: Alshati, Ali, et al.
Publicado: (2020)

High-grade B-Cell lymphoma with MYC and BCL6 rearrangements associated with Richter transformation of chronic lymphocytic leukemia
por: Rogers, Thomas S, et al.
Publicado: (2019)

P1232: PRINCIPLES OF PRECISION ONCOLOGY IN PRIMARY REFRACTORY HIGH-GRADE B-CELL LYMPHOMA WITH MYC-, BCL2 AND/OR BCL6 REARRANGEMENTS (HGBL-DH/TH)
por: Witte, H., et al.
Publicado: (2022)

Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma
por: Ye, Qing, et al.
Publicado: (2015)

High-grade B-cell lymphoma with MYC and BCL2 rearrangements arising in a composite lymphoma
por: Moore, Alison M., et al.
Publicado: (2018)

Gemcitabine, Dexamethasone, and Cisplatin Regimen as an Effective Salvage Therapy for High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
por: Mitobe, Masaki, et al.
Publicado: (2018)

Educational Case: Gastric High-Grade B-Cell Lymphoma With MYC and BCL2 Gene Rearrangement (Double-Hit Lymphoma)
por: Betts, Elham Vali, et al.
Publicado: (2020)

Systemic Inflammation and Tumour-Infiltrating T-Cell Receptor Repertoire Diversity Are Predictive of Clinical Outcome in High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
por: Olschewski, Vito, et al.
Publicado: (2021)

Primary CNS high-grade B-cell lymphoma, with rearrangements of MYC and BCL6 : a case report
por: Sasapu, Appalanaidu, et al.
Publicado: (2018)

High‐grade B‐cell lymphoma with MYC and BCL2 rearrangements with abundant multinucleated giant tumor cells
por: Zhang, Man, et al.
Publicado: (2023)

DA-EPOCH-R therapy for high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in a patient with renal dysfunction
por: Mitobe, Masaki, et al.
Publicado: (2021)

Patient stratification and identification of adverse event correlations in the space of 1190 drug related adverse events
por: Roitmann, Eva, et al.
Publicado: (2014)

Association of sex with clinical outcomes in COVID-19 patients: A retrospective analysis of 1190 cases
por: Liu, Jiao, et al.
Publicado: (2020)

1190. Hygiene of the Hands 90/90: A Program of Continuous Improvement for the Compliance of the Hygiene of the Hands
por: Trejo, Roxana, et al.
Publicado: (2019)

PB2161: CHARACTERISTICS OF AGGRESSIVE B-CELL LYMPHOMAS WITH MYC REARRANGEMENT
por: Ortuzar Pasalodos, A., et al.
Publicado: (2022)

Spontaneous Remission of an Untreated, MYC and BCL2 Coexpressing, High-Grade B-Cell Lymphoma: A Case Report and Literature Review
por: Potts, D. Alan, et al.
Publicado: (2017)

Elucidating a false-negative MYC break-apart fluorescence in situ hybridization probe study by next-generation sequencing in a patient with high-grade B-cell lymphoma with IGH/MYC and IGH/BCL2 rearrangements
por: Peterson, Jess F., et al.
Publicado: (2019)

Redefining the high‐grade B cell lymphoma with double/triple rearrangements of MYC and BCL2/BCL6 genes. Learning from a case report
por: Rodríguez‐Pinilla, Socorro María, et al.
Publicado: (2021)

Induction treatment in high-grade B-cell lymphoma with a concurrent MYC and BCL2 and/or BCL6 rearrangement: a systematic review and meta-analysis
por: Zeremski, Vanja, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_el2epjjb1hqum2hl7016pseklb